Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;14(20):5136.
doi: 10.3390/cancers14205136.

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M McGranahan  1 , Alipi V Bonm  2 , Jennifer M Specht  3 , Vyshak Venur  1   3 , Simon S Lo  4
Affiliations
Review

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Tresa M McGranahan et al. Cancers (Basel). .

Abstract

In the past 5 years, the treatment options available to patients with HER2+ breast cancer brain metastasis (BCBM) have expanded. The longer survival of patients with HER2+ BCBM renders understanding the toxicities of local therapies even more important to consider. After reviewing the available literature for HER2 _targeted systemic therapies as well as local therapies, we present a simplified algorithm for when to prioritize systemic therapies over local therapies in patients with HER2+ BCBM.

Keywords: Human Epidermal growth factor Receptor 2; brain metastasis; breast cancer.

PubMed Disclaimer

Conflict of interest statement

Vyshak Venur serves on the Seagen advisory board. The other authors declare no conflict of interest. Simon Lo is a member of the Gamma Knife (Elekta AB) ICON Expert Group.

Figures

Figure 1
Figure 1
Examples of objective response to HER2-_targeted therapy.
Figure 1
Figure 1
Examples of objective response to HER2-_targeted therapy.
Figure 2
Figure 2
Algorithm for Management of HER2+ Breast Cancer Brain Metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–2354. doi: 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B. - DOI - PubMed
    1. Kuksis M., Gao Y., Tran W., Hoey C., Kiss A., Komorowski A.S., Dhaliwal A.J., Sahgal A., Das S., Chan K.K., et al. The incidence of brain metastases among patients with metastatic breast cancer: A systematic review and meta-analysis. Neuro-Oncology. 2020;23:894–904. doi: 10.1093/neuonc/noaa285. - DOI - PMC - PubMed
    1. Albiges L., André F., Balleyguier C., Gomez-Abuin G., Chompret A., Delaloge S. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: Highly increased incidence of brain metastases. Ann. Oncol. 2005;16:1846–1847. doi: 10.1093/annonc/mdi351. - DOI - PubMed
    1. Song Y., Barry W.T., Seah D.S., Tung N.M., Garber J.E., Lin N.U. Patterns of recurrence and metastasis in BRCA1/BRCA2 -associated breast cancers. Cancer. 2019;126:271–280. doi: 10.1002/cncr.32540. - DOI - PMC - PubMed
    1. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., Crivellari D., Fey M.F., Murray E., Pagani O., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann. Oncol. 2006;17:935–944. doi: 10.1093/annonc/mdl064. - DOI - PubMed

Grants and funding

This research received no external funding.
  NODES
INTERN 1
twitter 2